ShareValue scores for 688553.SHG: Valuation 48, Quality 55, Growth 39, Health 59.

688553.SHG
SSE

Sichuan Huiyu Pharmaceutical Co Ltd

CN¥11.91(+7.59%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 16%
Valuation
48
Fair Value
Price vs Value
Quality
55
Moderate
Business Strength
Growth
39
Weak
Revenue & Earnings
Health
59
Moderate
Financial Stability
Momentum
8
Bearish
Price Trend

Company Details

About

Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, panosetron hydrochloride, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, thiotepa, teicoplanin, epirubicin hydrochloride, methotrexate, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorportaed in 2010 and is headquartered in Neijiang, China.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026